Immatics at the CAR-TCR Summit (Sept 10-13, 2019) in Boston, MA

| News

Join Immatics and others to engineer a cancer-free world at the 5th CAR-TCR Summit in Boston, Massachusetts. Do not miss the opportunity and get to know Immatics’ latest advances in TCR T-cell therapies.

 

Tuesday, September 10, 3-5pm EST

Strategic Dives

En Route to the Off-the-Shelf Future of Cellular Therapy

  • Evaluate the balance between tolerability and durable clinical response via persistence, which is paramount to the success of allogeneic cell therapy
  • Discuss how commercial viability will depend on large-scale expansion processes that preserve product fitness and potency, with minimal product heterogeneity
  • Review how first-generation modalities entering the clinic will shed light on some of these pressing questions

Speaker: Yannick Bulliard, Director Translational Development

 

 

Wednesday, September 11, 3:19-3:49pm EST

Translation Session

Explore Patient Clinical Data to Review In Vivo T-Cell Persistence

  • Manufacturing under cGMP conditions to meet safety and efficacy release criteria
  • Present in vivo data on T-cell persistence

Speaker: Ali Mohamed, VP CMC

 

We’re looking forward to interesting and exciting discussions.

You can find further information on the CAR-TCR Summit here.

Press Contact

Anja Heuer

Corporate Communications,
Immatics Biotechnologies GmbH

+49 89 540 415 606

Go back

We use cookies to ensure that we give you the best experience on our website.